Home > others & > Mitotane

Mitotane

米托坦,NCI-C04933,NCI-C 04933,NCI-C-04933

Mitotane是DDD的同分异构体和DDT的衍生物，有抗癌活性，可作用于肾上腺皮质癌。

目录号
EY1695
EY1695
纯度
99.27%
99.27%
规格
100 mg
500 mg
原价
496
820
售价
496
820
库存
现货
现货
订购
订购
订购
订购
订购
订购
具体折扣请咨询客服

  • 生物活性

    Mitotane, is an antineoplastic medication used in the treatment of adrenocortical carcinoma.

  • 体外研究

  • 体内研究

  • 激酶实验

  • 细胞实验

  • 动物实验

  • 不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数


    例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

  • 参考文献

    [1] Zatelli MC, et al. Endocrinology,?010, 151(6), 2453-2561.

    分子式
    C14H10Cl4    		 分子量
    320.04    		 CAS号
    53-19-0    		 储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂（常温）
    		 DMSO
    64 mg/mL    		 Water
    <1 mg/mL    		 Ethanol
    64 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT Number Conditions Interventions Sponsor/Collaborators Phases Start Date Last Updated
    NCT00777244 Adrenocortical Carcinoma Drug: MITOTANE University of Turin, Italy Phase 3 2008-04-01 2013-11-08
    NCT02057237 Prostate Cancer Drug: Mitotane University Health Network, Toronto Phase 1 2013-09-01 2015-11-11
    NCT00778817 Recurrent Adrenocortical Carcinoma|Stage III Adrenocortical Carcinoma|Stage IV Adrenocortical Carcinoma Biological: IMC-A12|Drug: mitotane National Cancer Institute (NCI) Phase 2 2008-12-01 2014-03-28
    NCT00568139 Adrenocortical Carcinoma University of Wuerzburg 2008-01-01 2016-10-28
    NCT03083834 Adrenal Insufficiency|Adrenal Cancer Diagnostic Test: Cosyntropin stimulation test Bnai Zion Medical Center 2017-04-01 2017-03-18
    NCT00001339 Adrenal Cortical Carcinoma Drug: doxorubicin, vincristine, and etoposide with mitotane National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Phase 2 1993-08-01 2008-03-03
    NCT00071058 Adrenal Cortex Neoplasms Drug: XR9576 (Tariquidar) National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Phase 2 2003-10-01 2012-09-12
    NCT00094497 Carcinoma, Adrenal Cortical Drug: Etoposide|Drug: Doxorubicin|Drug: Cisplatin|Drug: Streptozotocin|Drug: Mitotane Collaborative Group for Adrenocortical Carcinoma Treatment|German Federal Ministry of Education and Research|National Cancer Institute (NCI) Phase 3 2004-06-01 2016-09-19
    NCT00304070 Stage I Adrenocortical Carcinoma|Stage II Adrenocortical Carcinoma|Stage III Adrenocortical Carcinoma|Stage IV Adrenocortical Carcinoma Drug: doxorubicin hydrochloride|Procedure: conventional surgery|Drug: cisplatin|Drug: mitotane|Drug: etoposide|Biological: filgrastim Children's Oncology Group|National Cancer Institute (NCI) Phase 3 2006-09-01 2016-03-17
    NCT00215202 Nonresectable Adrenocortical Carcinoma Drug: Iressa (ZD1839) Dartmouth-Hitchcock Medical Center|AstraZeneca|M.D. Anderson Cancer Center|Dana-Farber Cancer Institute|Kentuckiana Cancer Institute Phase 2 2004-08-01 2008-08-13
    NCT02788201 Urothelial Carcinoma|Bladder Cancer|Urinary Bladder Neoplasms Drug: 75 approved agents|Other: COXEN National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Phase 2 2016-05-20 2017-01-24
    NCT00453674 Adrenocortical Carcinoma University of Wuerzburg|Deutsche Krebshilfe e.V., Bonn (Germany) 2003-01-01 2016-10-28

    注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 ：
  • 收件地址 ：
  • 电话号码 ：
  • 单位名称 ：
  • 产品货号 ：
  • 产品规格 ：
  • 发票抬头以及单位税号 ：